We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

CORMAY

Cormay develops and manufactures diagnostic reagents and laboratory equipment, including hematology analyzers and cli... read more Featured Products: More products

Download Mobile App





Cormay Diagnostics Introduces True 5+ DIFF Multi-Patented Hematology Solution at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022

Cormay Diagnostics (Warsaw, Poland) is participating in this year’s edition of MEDICA, where the company is presenting its range of high quality diagnostic reagents and advanced laboratory analyzers. More...

At MEDICA 2022, Cormay is showcasing the MYTHIC 70, a true 5+DIFF hematology analyzer that delivers 29 parameters in less than 60 seconds. Its superior technology ensures reliability and multi-patented solution with unmatchable cost savings. It features walk away function and allows loading of 50 samples for improving laboratory efficiency. Alongside the MYTHIC 70, Cormay is exhibiting the MYTHIC 3CRP, a 3 DIFF hematology analyzer that offers a two-in-one solution. The MYTHIC 3CRP analyzer is designed to analyze whole blood samples, including measurement of blood cell count, hemoglobin concentration, CRP concentration and 3-part leukocytes differentiation.

In addition to its range of hematology analyzers, Cormay is also highlighting its portfolio of chemistry analyzers, including the ACCENT M320 and ACCENT S120. The ACCENT M320 and ACCENT S120 are computer-controlled, fully-automated chemistry analyzers for in-vitro diagnostic use in clinical laboratories to measure activity or concentration of clinical chemistry parameters in serum, plasma, urine and cerebrospinal fluid samples. Together with the highest quality dedicated reagent line, calibrators and controls, they provide a complete solution suitable for small to mid-size laboratories.

Among its urine analyzers being showcased by Cormay at MEDICA 2022 are the Uri-Tex and URI-TEX 300 semi-automatic urine chemistry analyzers. Designed to be used with Cormay urinalysis strips, the intelligent Uri-Tex image analyzer locates the strip and the pads, reads the color data, and based on these, determines the parameter values. Its intuitive device operation makes analysis easy and allows for fast determination of multiple chemical compounds in urine. Similarly, the Uri-Tex 300 semiautomatic urine chemistry analyzer is also designed to be used with Cormay urinalysis strips and determines the multiple parameters values in urine in less than a minute. The operator is only required to dip the strips into the samples and place them on the strips loading plate which allows for a maximum of 10 strips to be loaded at one time.

Related Links:
Cormay Diagnostics


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.